Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 1/2 3Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 3Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 19INDUSTRY 6NETWORK 2FED 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 3Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Pluvicto × Clear all
NCT05849298 2026-05-27

PSMACare

Novartis

Phase 2 Active not recruiting
49 enrolled
Genitourinary

Prostatic Neoplasms

NCT05114746 2026-05-08

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Novartis

Phase 2 Completed
94 enrolled
Genitourinary

Prostatic Neoplasms

NCT06894511 2026-05-01

PSMAndARPI

Novartis

Phase 2 Active not recruiting
7 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118 2026-05-01

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Novartis

Phase 2 Active not recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Novartis

Phase 2 Recruiting
20 enrolled

Renal Insufficiency

NCT03042312 2021-03-24

RESIST-PC

Endocyte

Phase 2 Terminated
71 enrolled 15 charts
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡